Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $29.05

Key Points

• Intellia Therapeutics has received a consensus recommendation of "Moderate Buy" from nineteen brokerages, with an average price target of $29.05 for the stock.
• Insider transactions revealed that EVP Edward J. Dulac III sold 7,462 shares, resulting in a 6.57% decrease in his ownership stake in the company.
• The company reported a revenue of $14.25 million for the recent quarter, significantly exceeding analysts' estimates and marking a 104.3% increase year-over-year.

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nineteen ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $29.0526.

Several research firms recently commented on NTLA. Guggenheim reaffirmed a "buy" rating and set a $14.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, August 13th. HC Wainwright decreased their target price on Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Chardan Capital reduced their price target on Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Citigroup reduced their target price on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Finally, Royal Bank Of Canada lowered their target price on Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating for the company in a research note on Friday, August 8th.

Insider Transactions at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total transaction of $104,617.24. Following the transaction, the executive vice president owned 106,062 shares in the company, valued at $1,486,989.24. The trade was a 6.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 12,534 shares of company stock worth $153,837. 3.10% of the stock is owned by insiders.

Institutional Trading of Intellia Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Intellia Therapeutics by 51.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company's stock valued at $140,000 after purchasing an additional 6,722 shares during the last quarter. D.A. Davidson & CO. raised its stake in Intellia Therapeutics by 76.2% in the first quarter. D.A. Davidson & CO. now owns 26,020 shares of the company's stock worth $185,000 after buying an additional 11,250 shares in the last quarter. California State Teachers Retirement System raised its stake in Intellia Therapeutics by 4.1% in the fourth quarter. California State Teachers Retirement System now owns 90,638 shares of the company's stock worth $1,057,000 after buying an additional 3,596 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Intellia Therapeutics during the fourth quarter worth $4,793,000. Finally, Baker BROS. Advisors LP acquired a new position in shares of Intellia Therapeutics in the 4th quarter valued at $7,510,000. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Stock Up 0.2%

Intellia Therapeutics stock traded up $0.0250 during trading hours on Monday, hitting $10.2350. The stock had a trading volume of 1,354,652 shares, compared to its average volume of 4,094,991. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -2.18 and a beta of 2.31. Intellia Therapeutics has a one year low of $5.90 and a one year high of $24.16. The business's 50 day simple moving average is $11.00 and its 200-day simple moving average is $9.52.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.04. The firm had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business's quarterly revenue was up 104.3% on a year-over-year basis. During the same period last year, the company earned ($1.52) earnings per share. Research analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.